Corneal features in trastuzumab emtansine treatment: not a rare occurrence
- 28 February 2019
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 175 (2) , 525-530
Abstract
Ado-trastuzumab emtansine (T-DM1/Kadcyla®;Genentech) is an antibody-drug conjugate used in the treatment of human epidermal growth factor receptor-2-positive metastasized breast cancer. Few studies report a spectrum of corneal changes in patients treated with this drug. Our aim is to specify the nature and prevalence of corneal features of T-DM1 treatment in order to formulate guidelines as to which findings necessitate systemic treatment cessation or dose reduction.Keywords
This publication has 15 references indexed in Scilit:
- Abnormal Corneal Lesions Induced by Trastuzumab EmtansineCornea, 2016
- New developments for antibody-drug conjugate-based therapeutic approachesCurrent Opinion in Immunology, 2016
- Antibody‐Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer TherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case reportBMC Cancer, 2015
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical TrialsJournal of Ocular Pharmacology and Therapeutics, 2015
- The Role of Endogenous Epidermal Growth Factor Receptor Ligands in Mediating Corneal Epithelial HomeostasisInvestigative Ophthalmology & Visual Science, 2014
- Role of ErbB2 in Corneal Epithelial Wound HealingInvestigative Ophthalmology & Visual Science, 2004
- Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye TestsCornea, 2003
- Cytarabine-induced corneal toxicityEye, 2003
- In vivo confocal microscopy of the human corneaBritish Journal of Ophthalmology, 2003